About CytRx Corporation
CytRx Corporation is a biopharmaceutical research and development company specializing in oncology. The Company is focused on the clinical development of aldoxorubicin, its modified version of the chemotherapeutic agent, doxorubicin. It is engaged in Phase III trials for aldoxorubicin as a therapy for patients with soft tissue sarcoma (STS) whose tumors have progressed after treatment with chemotherapy. It is also involved in evaluating aldoxorubicin in a Phase IIb clinical trial in small cell lung cancer; a Phase II clinical trial in human immunodeficiency virus-related Kaposi's sarcoma; a Phase II clinical trial in patients with late-stage glioblastoma (brain cancer); a Phase Ib trial in combination with ifosfamide in patients with STS, and a Phase Ib trial in combination with gemcitabine in subjects with metastatic solid tumors. It is engaged in the pre-clinical development for DK049, an anti-cancer drug conjugate that utilizes its Linker Activated Drug Release (LADR) technology.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Biotechnology
- Sub-Industry: N/A
- Exchange: NASDAQ
- Symbol: CYTR
- Previous Close: $0.46
- 50 Day Moving Average: $0.4218
- 200 Day Moving Average: $0.4985
- 52-Week Range: $0.36 - $3.66
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -0.92
- P/E Growth: 0.0000
- Market Cap: $44.58M
- Outstanding Shares: 96,943,000
- Beta: 1.34
- Return on Equity: -213.82%
- Return on Assets: -99.93%
Companies Related to CytRx Corporation:
- Debt-to-Equity Ratio: 0.86%
- Current Ratio: 3.06%
- Quick Ratio: 3.06%
Earnings History for CytRx Corporation (NASDAQ:CYTR)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|3/9/2017|| || || || || || || || |
Earnings Estimates for CytRx Corporation (NASDAQ:CYTR)
Current Year EPS Consensus Estimate: $-0.7000 EPS
Next Year EPS Consensus Estimate: $-0.5000 EPS
(Data provided by Zacks Investment Research)
|Quarter||Number of Estimates||Low Estimate||High Estimate||Average Estimate|
Dividend History for CytRx Corporation (NASDAQ:CYTR)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading History for CytRx Corporation (NASDAQ:CYTR)
Insider Ownership Percentage: 12.40%
Institutional Ownership Percentage: 20.19%
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|12/3/2013||Scott Bradford Patterson||major shareholder||Buy||284,979||$2.44||$695,348.76|| |
|11/7/2013||Scott Bradford Patterson||Major Shareholder||Buy||50,000||$2.06||$103,000.00|| |
|4/1/2013||Scott Bradford Patterson||Major Shareholder||Buy||4,083||$2.70||$11,024.10|| |
|3/20/2013||Scott Bradford Patterson||Major Shareholder||Buy||3,980||$2.61||$10,387.80|| |
|3/13/2013||Scott Bradford Patterson||Major Shareholder||Buy||55,360||$2.67||$147,811.20|| |
|10/22/2012||Scott Bradford Patterson||Major Shareholder||Buy||180,000||$2.51||$451,800.00|| |
|10/18/2012||Scott Bradford Patterson||Major Shareholder||Buy||1,200,000||$2.50||$3,000,000.00|| |
Latest Headlines for CytRx Corporation (NASDAQ:CYTR)
What is CytRx Corporation's stock symbol?
CytRx Corporation trades on the NASDAQ under the ticker symbol "CYTR."
Where is CytRx Corporation's stock going? Where will CytRx Corporation's stock price be in 2017?
4 brokerages have issued twelve-month price objectives for CytRx Corporation's shares. Their predictions range from $0.75 to $12.00. On average, they expect CytRx Corporation's share price to reach $4.10 in the next year.
When will CytRx Corporation announce their earnings?
CytRx Corporation is scheduled to release their next quarterly earnings announcement on Thursday, March, 9th 2017.
Who owns CytRx Corporation stock?
CytRx Corporation's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include State Street Corp (1.00%).
Who bought CytRx Corporation stock? Who is buying CytRx Corporation stock?
CytRx Corporation's stock was purchased by a variety of institutional investors in the last quarter, including State Street Corp.
How do I buy CytRx Corporation stock?
Shares of CytRx Corporation can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How much does a share of CytRx Corporation stock cost?
One share of CytRx Corporation stock can currently be purchased for approximately $0.46.
CytRx Corporation (NASDAQ:CYTR) Chart for Wednesday, February, 22, 2017
Institutional Ownership ChartEarnings History ChartDividend History Chart